The Valley Desk

NCT04165083 · Interventional trial

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

Overall registry status Completed

Phase 2

Conditions Carcinoma, Non-Small-Cell Lung

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov